VAFP
MRTX

Vahanian & Associates Financial Planning’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,275
Closed -$230K – 64
2023
Q3 		$230K Buy
+5,275
New +$188K 0.74% 52

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Vahanian & Associates Financial Planning's MRTX Position: Q4 2023 in Review

Vahanian & Associates Financial Planning sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 5,275 shares — an estimated $230K sold.

Vahanian & Associates Financial Planning first reported a position in MRTX in Q3 2023 and held it in 1 quarter. The position peaked at $230K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Vahanian & Associates Financial Planning reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Vahanian & Associates Financial Planning sold 5,275 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $230K.
  • Vahanian & Associates Financial Planning first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Vahanian & Associates Financial Planning's Mirati Therapeutics, Inc. Common Stock position peaked at $230K in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Vahanian & Associates Financial Planning's 13F filing for Q4 2023, filed 25 Jan 2024.